查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1888676

醫藥中心和病患准入支援服務市場規模、佔有率和趨勢分析報告：按服務類型、產品類型、地區和細分市場預測（2025-2033 年）

Pharma Hub And Patient Access Support Service Market Size, Share & Trends Analysis Report By Service Type, By Service Delivery Type, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

全球醫藥中心與病患准入支援服務市場摘要

2024 年全球醫藥中心和病患准入支援服務市場規模估計為 32.4 億美元，預計到 2033 年將達到 76.3 億美元。

預計從 2025 年到 2033 年，該行業將以 10.0% 的複合年成長率成長。這一成長是由對各種專科和罕見疾病/孤兒病新藥的需求不斷成長以及優先構建以患者為中心的生態系統所推動的。

支付方複雜性增加（事先核准、特殊藥品清單、索賠拒絕增加）和更嚴格的成本效益控制正在促使製造商將患者入院活動外包，並從專門的中心提供者那裡受益，以進行檢驗活動和共同支付/費用援助管理。

2021年至2024年間，高成本專科藥物和罕見疾病藥物的不斷湧現，是推動藥品中心和病人用藥支持服務擴張的主要動力。根據美國食品藥物管理局（FDA）統計，2022年共核准了37種新藥，其中20種（約佔54%）為罕見疾病藥物。 2023年，又有55種新藥核准，其中28種（佔絕大多數）為罕見疾病藥物。這些治療方法價格往往高昂，且需要複雜的保險核准流程。

2022年核准B型血友病的基因療法HemGenix，每劑費用約350萬美元；而2023年核准用於治療阿茲海默症Rekemvi，每年費用約2.65萬美元。這些新藥的問世凸顯了病患在經濟和行政方面面臨的日益嚴峻的挑戰，促使製藥公司大力投資於數位化平台、福利核實系統、預先核准自動化以及病患援助計畫。由此導致的專業化且高成本治療方法的激增，直接推動了對整合式醫療中心和患者服務解決方案的需求，這些方案旨在簡化報銷流程、加快治療啟動速度並提高患者的用藥依從性。

此外，市場正受到多家公司推行的多項策略措施的推動。例如，2023年11月，Docquity宣布將把其數位化病患服務計畫DocquityCare PAP拓展至泰國。該公司致力於透過在泰國推出五個PAP項目，並為250名認證醫療專業人員和約100家註冊醫院提供支持，從而改善癌症和其他危及生命的疾病患者的護理。

目錄

第1章調查方法和範圍

第2章執行摘要

第3章 市場變數、趨勢與範圍

  • 市場趨勢展望
  • 市場動態
  • 商業環境分析
    • 波特五力分析
    • PESTLE分析

4. 醫藥中心和病人准入支持服務市場：按服務類型分類的估算和趨勢分析

  • 按服務類型分類的市場佔有率變化分析（2024 年和 2033 年）
  • 按服務類型分類的市場規模、預測和趨勢分析（2021-2033 年）
  • 專案註冊
    • 訂單處理
    • 應用程式處理
    • 註冊方式的便利性（電話、現場、透過入口網站、應用程式）
    • 程式數據
  • 治療導航員
    • 製程流程圖和標準作業程式
    • 節目材料和腳本
    • 護理團隊培訓
    • 系統測試與最佳化
  • 報銷服務/成本降低服務
  • 臨床負責人
  • 協調專科藥局和配藥業務
  • 其他

5. 醫藥中心和病人准入支持服務市場：按服務類型分類的估算和趨勢分析

  • 按產品類型分類的市佔率變化分析（2024 年和 2033 年）
  • 按產品類型分類的市場規模、預測和趨勢分析（2021-2033 年）
  • 整合服務
  • 獨立服務

6. 醫藥中心和病人准入支持服務市場：區域估算和趨勢分析

  • 區域市場概覽
  • 區域市場：主要結論
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第7章 競爭情勢

  • 參與公司概況
  • 企業市場分析/企業市場占有率分析（2024）
  • 公司分類
  • 策略規劃
  • 公司簡介/上市公司
    • Valeris（Formerly PharmaCord）
    • Fortrea
    • AssistRx
    • CareMetx, LLC
    • ConnectiveRx
    • Lash Group
    • McKesson Corporation
    • Engage
    • NS Pharma, Inc.（a wholly owned subsidiary of Nippon Shinyaku Co., Ltd.）
    • Cardinal Health
    • Envoy Health, Inc.
    • EVERSANA
    • United BioSource LLC
    • Mercalis
    • Sciensus
Product Code: GVR-4-68040-278-6

Pharma Hub And Patient Access Support Service Market Summary

The global pharma hub and patient access support service market size was estimated at USD 3.24 billion in 2024 and is projected to reach USD 7.63 billion by 2033, growing at a CAGR of 10.0% from 2025 to 2033. The growth is attributed to the increasing need to administer new medicines for various specialties and rare & orphan diseases, prioritizing creating a patient-centric ecosystem.

Payer-side complexity (prior authorizations, specialty drug formularies, and rising claim denials), and tighter affordability controls have pushed manufacturers to outsource patient onboarding, benefiting verification and copay/cost-assistance management to dedicated hub providers.

The growing launch of high-cost specialty and rare-disease therapies between 2021 and 2024 has become a key driver for the expansion of pharma hubs and patient access support services. According to the U.S. FDA, 37 novel drugs were approved in 2022, of which 20 around 54% were targeted at rare diseases, while in 2023, 55 new drugs were approved, and over half, 28 drugs, were for rare diseases. These therapies often carry exceptionally high price tags and require complex insurance approvals.

Hemgenix, a gene therapy for hemophilia B approved in 2022, was priced at about USD 3.5 million per dose, and Alzheimer's drug Leqembi, approved in 2023, costs around USD 26,500 annually. Such launches highlight the growing financial and administrative barriers for patients, encouraging pharmaceutical companies to invest heavily in digital hub platforms, benefit verification systems, prior authorization automation, and patient support programs. As a result, the increasing number of specialized, high-cost therapies is directly driving demand for integrated pharma hub and patient access support solutions to streamline reimbursement, accelerate therapy initiation, and improve adherence outcomes.

The market is further driven by players undertaking several strategic initiatives. For instance, in November 2023, Docquity announced the expansion of its digitized patient access program, DocquityCare PAP, to Thailand. It launched five PAPs in Thailand, supporting 250 authorized HCPs and around 100 enrolled hospitals to enhance patient care for individuals with cancer and additional life-threatening conditions.

Global Pharma Hub And Patient Access Support Service Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global pharma HUB and patient access support service market report based on service type, service delivery type, and region:

  • Service Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Program Enrollment
    • Order processing
    • Application processing
    • Ease of enrollment (through phone, face, portal, or app)
    • Program data
  • Treatment Navigators
    • Process flows and standard operating procedures
    • Program literature and scripts
    • Care team training
    • Systems testing and optimization
  • Reimbursement Services/Affordability Services
  • Clinical Educator
  • Coordination of Specialty Pharmacy/Dispensing
  • Others
  • Service Delivery Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Integrated Services
  • Standalone Services
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Service Type
    • 1.2.2. Service Delivery Type
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Rising Launch of Specialty and Rare-Disease Therapies
      • 3.2.1.2. Need to Simplify Patient Enrollment and Therapy Access
      • 3.2.1.3. Growing Emphasis on Patient-Centric Care
      • 3.2.1.4. Increasing Regulatory and Compliance Requirements
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High implementation and operational costs
      • 3.2.2.2. Data Privacy and Regulatory Compliance Challenges
    • 3.2.3. Industry Opportunity Analysis
    • 3.2.4. Industry Challenge Analysis
    • 3.2.5. Technology Overview
    • 3.2.6. Case Studies
  • 3.3. Business Environment Analysis
    • 3.3.1. Porter's Five Forces Analysis
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTLE Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic and Social landscape
      • 3.3.2.3. Technological landscape
      • 3.3.2.4. Environmental landscape
      • 3.3.2.5. Legal Landscape

Chapter 4. Pharma HUB and Patient Access Support Service Market: Service Type Estimates & Trend Analysis

  • 4.1. Service Type Segment Dashboard
  • 4.2. Service Type Market Share Movement Analysis, 2024 & 2033
  • 4.3. Market Size & Forecasts and Trend Analysis, by Service Type, 2021 to 2033 (USD Million)
  • 4.4. Program Enrollment
    • 4.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.2. Order processing
      • 4.4.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.3. Application processing
      • 4.4.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.4. Ease of enrollment (through phone, face, portal, or app)
      • 4.4.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.5. Program data
      • 4.4.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Treatment Navigators
    • 4.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.2. Process flows and standard operating procedures
      • 4.5.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.3. Program literature and scripts
      • 4.5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.4. Care team training
      • 4.5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.5. Systems testing and optimization
      • 4.5.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6. Reimbursement Services/Affordability Services
    • 4.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.7. Clinical Educator
    • 4.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.8. Coordination of Specialty Pharmacy/Dispensing
    • 4.8.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.9. Others
    • 4.9.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Pharma HUB and Patient Access Support Service Market: Delivery Type Estimates & Trend Analysis

  • 5.1. Delivery Segment Dashboard
  • 5.2. Delivery Market Share Movement Analysis, 2024 & 2033
  • 5.3. Market Size & Forecasts and Trend Analysis, by Delivery, 2021 to 2033 (USD Million)
  • 5.4. Integrated Services
    • 5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Standalone Services
    • 5.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Pharma HUB and Patient Access Support Service Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Dashboard
  • 6.2. Regional Market: Key Takeaways
  • 6.3. North America
    • 6.3.1. North America Pharma HUB and Patient Access Support Service market estimates and forecasts, 2021 - 2033 (USD Million)
    • 6.3.2. U.S.
      • 6.3.2.1. Key country dynamic
      • 6.3.2.2. Regulatory framework
      • 6.3.2.3. Competitive insights
      • 6.3.2.4. U.S. Pharma HUB and Patient Access Support Service market estimates and forecasts, 2021 - 2033 (USD Million)
    • 6.3.3. Canada
      • 6.3.3.1. Key country dynamic
      • 6.3.3.2. Regulatory framework
      • 6.3.3.3. Competitive insights
      • 6.3.3.4. Canada Pharma HUB and Patient Access Support Service market estimates and forecasts, 2021 - 2033 (USD Million)
    • 6.3.4. Mexico
      • 6.3.4.1. Key country dynamic
      • 6.3.4.2. Regulatory framework
      • 6.3.4.3. Competitive insights
      • 6.3.4.4. Mexico Pharma HUB and Patient Access Support Service market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.4. Europe
    • 6.4.1. Europe Pharma HUB and Patient Access Support Service market estimates and forecasts, 2021 - 2033 (USD Million)
    • 6.4.2. Germany
      • 6.4.2.1. Key country dynamic
      • 6.4.2.2. Regulatory framework
      • 6.4.2.3. Competitive insights
      • 6.4.2.4. Germany Pharma HUB and Patient Access Support Service market estimates and forecasts, 2021 - 2033 (USD Million)
    • 6.4.3. UK
      • 6.4.3.1. Key country dynamic
      • 6.4.3.2. Regulatory framework
      • 6.4.3.3. Competitive insights
      • 6.4.3.4. UK Pharma HUB and Patient Access Support Service market estimates and forecasts, 2021 - 2033 (USD Million)
    • 6.4.4. France
      • 6.4.4.1. Key country dynamic
      • 6.4.4.2. Regulatory framework
      • 6.4.4.3. Competitive insights
      • 6.4.4.4. France Pharma HUB and Patient Access Support Service market estimates and forecasts, 2021 - 2033 (USD Million)
    • 6.4.5. Italy
      • 6.4.5.1. Key country dynamic
      • 6.4.5.2. Regulatory framework
      • 6.4.5.3. Competitive insights
      • 6.4.5.4. Italy Pharma HUB and Patient Access Support Service market estimates and forecasts, 2021 - 2033 (USD Million)
    • 6.4.6. Spain
      • 6.4.6.1. Key country dynamic
      • 6.4.6.2. Regulatory framework
      • 6.4.6.3. Competitive insights
      • 6.4.6.4. Spain Pharma HUB and Patient Access Support Service market estimates and forecasts, 2021 - 2033 (USD Million)
    • 6.4.7. Denmark
      • 6.4.7.1. Key country dynamic
      • 6.4.7.2. Regulatory framework
      • 6.4.7.3. Competitive insights
      • 6.4.7.4. Denmark Pharma HUB and Patient Access Support Service market estimates and forecasts, 2021 - 2033 (USD Million)
    • 6.4.8. Sweden
      • 6.4.8.1. Key country dynamic
      • 6.4.8.2. Regulatory framework
      • 6.4.8.3. Competitive insights
      • 6.4.8.4. Sweden Pharma HUB and Patient Access Support Service market estimates and forecasts, 2021 - 2033 (USD Million)
    • 6.4.9. Norway
      • 6.4.9.1. Key country dynamic
      • 6.4.9.2. Regulatory framework
      • 6.4.9.3. Competitive insights
      • 6.4.9.4. Norway Pharma HUB and Patient Access Support Service market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.5. Asia Pacific
    • 6.5.1. Asia Pacific Pharma HUB and Patient Access Support Service market estimates and forecasts, 2021 - 2033 (USD Million)
    • 6.5.2. Japan
      • 6.5.2.1. Key country dynamic
      • 6.5.2.2. Regulatory framework
      • 6.5.2.3. Competitive insights
      • 6.5.2.4. Japan Pharma HUB and Patient Access Support Service market estimates and forecasts, 2021 - 2033 (USD Million)
    • 6.5.3. China
      • 6.5.3.1. Key country dynamic
      • 6.5.3.2. Regulatory framework
      • 6.5.3.3. Competitive insights
      • 6.5.3.4. China Pharma HUB and Patient Access Support Service market estimates and forecasts, 2021 - 2033 (USD Million)
    • 6.5.4. India
      • 6.5.4.1. Key country dynamic
      • 6.5.4.2. Regulatory framework
      • 6.5.4.3. Competitive insights
      • 6.5.4.4. India Pharma HUB and Patient Access Support Service market estimates and forecasts, 2021 - 2033 (USD Million)
    • 6.5.5. South Korea
      • 6.5.5.1. Key country dynamic
      • 6.5.5.2. Regulatory framework
      • 6.5.5.3. Competitive insights
      • 6.5.5.4. South Korea Pharma HUB and Patient Access Support Service market estimates and forecasts, 2021 - 2033 (USD Million)
    • 6.5.6. Australia
      • 6.5.6.1. Key country dynamic
      • 6.5.6.2. Regulatory framework
      • 6.5.6.3. Competitive insights
      • 6.5.6.4. Australia Pharma HUB and Patient Access Support Service market estimates and forecasts, 2021 - 2033 (USD Million)
    • 6.5.7. Thailand
      • 6.5.7.1. Key country dynamic
      • 6.5.7.2. Regulatory framework
      • 6.5.7.3. Competitive insights
      • 6.5.7.4. Thailand Pharma HUB and Patient Access Support Service market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.6. Latin America
    • 6.6.1. Latin America Pharma HUB and Patient Access Support Service Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.2. Brazil
      • 6.6.2.1. Key country dynamic
      • 6.6.2.2. Regulatory framework
      • 6.6.2.3. Competitive insights
      • 6.6.2.4. Brazil Pharma HUB and Patient Access Support Service market estimates and forecasts, 2021 - 2033 (USD Million)
    • 6.6.3. Argentina
      • 6.6.3.1. Key country dynamic
      • 6.6.3.2. Regulatory framework
      • 6.6.3.3. Competitive insights
      • 6.6.3.4. Argentina Pharma HUB and Patient Access Support Service market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.7. MEA
    • 6.7.1. MEA Pharma HUB and Patient Access Support Service market estimates and forecasts, 2021 - 2033 (USD Million)
    • 6.7.2. South Africa
      • 6.7.2.1. Key country dynamic
      • 6.7.2.2. Regulatory framework
      • 6.7.2.3. Competitive insights
      • 6.7.2.4. South Africa Pharma HUB and Patient Access Support Service market estimates and forecasts, 2021 - 2033 (USD Million)
    • 6.7.3. Saudi Arabia
      • 6.7.3.1. Key country dynamic
      • 6.7.3.2. Regulatory framework
      • 6.7.3.3. Competitive insights
      • 6.7.3.4. Saudi Arabia Pharma HUB and Patient Access Support Service market estimates and forecasts, 2021 - 2033 (USD Million)
    • 6.7.4. UAE
      • 6.7.4.1. Key country dynamic
      • 6.7.4.2. Regulatory framework
      • 6.7.4.3. Competitive insights
      • 6.7.4.4. UAE Pharma HUB and Patient Access Support Service market estimates and forecasts, 2021 - 2033 (USD Million)
    • 6.7.5. Kuwait
      • 6.7.5.1. Key country dynamic
      • 6.7.5.2. Regulatory framework
      • 6.7.5.3. Competitive insights
      • 6.7.5.4. Kuwait Pharma HUB and Patient Access Support Service market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis/Company Market Share Analysis (2024)
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. Valeris (Formerly PharmaCord)
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial performance
      • 7.5.1.3. Product benchmarking
      • 7.5.1.4. Strategic initiatives
    • 7.5.2. Fortrea
      • 7.5.2.1. Overview
      • 7.5.2.2. Financial performance
      • 7.5.2.3. Product benchmarking
      • 7.5.2.4. Strategic initiatives
    • 7.5.3. AssistRx
      • 7.5.3.1. Overview
      • 7.5.3.2. Financial performance
      • 7.5.3.3. Product benchmarking
      • 7.5.3.4. Strategic initiatives
    • 7.5.4. CareMetx, LLC
      • 7.5.4.1. Overview
      • 7.5.4.2. Financial performance
      • 7.5.4.3. Product benchmarking
      • 7.5.4.4. Strategic initiatives
    • 7.5.5. ConnectiveRx
      • 7.5.5.1. Overview
      • 7.5.5.2. Financial performance
      • 7.5.5.3. Product benchmarking
      • 7.5.5.4. Strategic initiatives
    • 7.5.6. Lash Group
      • 7.5.6.1. Overview
      • 7.5.6.2. Financial performance
      • 7.5.6.3. Product benchmarking
      • 7.5.6.4. Strategic initiatives
    • 7.5.7. McKesson Corporation
      • 7.5.7.1. Overview
      • 7.5.7.2. Financial performance
      • 7.5.7.3. Product benchmarking
      • 7.5.7.4. Strategic initiatives
    • 7.5.8. Engage
      • 7.5.8.1. Overview
      • 7.5.8.2. Financial performance
      • 7.5.8.3. Product benchmarking
      • 7.5.8.4. Strategic initiatives
    • 7.5.9. NS Pharma, Inc. (a wholly owned subsidiary of Nippon Shinyaku Co., Ltd.)
      • 7.5.9.1. Overview
      • 7.5.9.2. Financial performance
      • 7.5.9.3. Product benchmarking
      • 7.5.9.4. Strategic initiatives
    • 7.5.10. Cardinal Health
      • 7.5.10.1. Overview
      • 7.5.10.2. Financial performance
      • 7.5.10.3. Product benchmarking
      • 7.5.10.4. Strategic initiatives
    • 7.5.11. Envoy Health, Inc.
      • 7.5.11.1. Overview
      • 7.5.11.2. Financial performance
      • 7.5.11.3. Product benchmarking
      • 7.5.11.4. Strategic initiatives
    • 7.5.12. EVERSANA
      • 7.5.12.1. Overview
      • 7.5.12.2. Financial performance
      • 7.5.12.3. Product benchmarking
      • 7.5.12.4. Strategic initiatives
    • 7.5.13. United BioSource LLC
      • 7.5.13.1. Overview
      • 7.5.13.2. Financial performance
      • 7.5.13.3. Product benchmarking
      • 7.5.13.4. Strategic initiatives
    • 7.5.14. Mercalis
      • 7.5.14.1. Overview
      • 7.5.14.2. Financial performance
      • 7.5.14.3. Product benchmarking
      • 7.5.14.4. Strategic initiatives
    • 7.5.15. Sciensus
      • 7.5.15.1. Overview
      • 7.5.15.2. Financial performance
      • 7.5.15.3. Product benchmarking
      • 7.5.15.4. Strategic initiatives

List of Tables

  • Table 1 List of secodary sources
  • Table 2 List of abbreviation
  • Table 3 North America pharma HUB and patient access support service market, by region, 2021 - 2033 (USD Million)
  • Table 4 North America pharma HUB and patient access support service market, by service type, 2021 - 2033 (USD Million)
  • Table 5 North America pharma HUB and patient access support service market, by service delivery type, 2021 - 2033 (USD Million)
  • Table 6 U.S pharma HUB and patient access support service market, by service type, 2021 - 2033 (USD Million)
  • Table 7 U.S pharma HUB and patient access support service market, by service delivery type, 2021 - 2033 (USD Million)
  • Table 8 Canada pharma HUB and patient access support service market, by service type, 2021 - 2033 (USD Million)
  • Table 9 Canada pharma HUB and patient access support service market, by service delivery type, 2021 - 2033 (USD Million)
  • Table 10 Mexico pharma HUB and patient access support service market, by service type, 2021 - 2033 (USD Million)
  • Table 11 Mexico pharma HUB and patient access support service market, by service delivery type, 2021 - 2033 (USD Million)
  • Table 12 Europe pharma HUB and patient access support service market, by region, 2021 - 2033 (USD Million)
  • Table 13 Europe pharma HUB and patient access support service market, by service type, 2021 - 2033 (USD Million)
  • Table 14 Europe pharma HUB and patient access support service market, by service delivery type, 2021 - 2033 (USD Million)
  • Table 15 Germany pharma HUB and patient access support service market, by service type, 2021 - 2033 (USD Million)
  • Table 16 Germany pharma HUB and patient access support service market, by service delivery type, 2021 - 2033 (USD Million)
  • Table 17 UK pharma HUB and patient access support service market, by service type, 2021 - 2033 (USD Million)
  • Table 18 UK pharma HUB and patient access support service market, by service delivery type, 2021 - 2033 (USD Million)
  • Table 19 France pharma HUB and patient access support service market, by service type, 2021 - 2033 (USD Million)
  • Table 20 France pharma HUB and patient access support service market, by service delivery type, 2021 - 2033 (USD Million)
  • Table 21 Italy pharma HUB and patient access support service market, by service type, 2021 - 2033 (USD Million)
  • Table 22 Italy pharma HUB and patient access support service market, by service delivery type, 2021 - 2033 (USD Million)
  • Table 23 Spain pharma HUB and patient access support service market, by service type, 2021 - 2033 (USD Million)
  • Table 24 Spain pharma HUB and patient access support service market, by service delivery type, 2021 - 2033 (USD Million)
  • Table 25 Denmark pharma HUB and patient access support service market, by service type, 2021 - 2033 (USD Million)
  • Table 26 Denmark pharma HUB and patient access support service market, by service delivery type, 2021 - 2033 (USD Million)
  • Table 27 Sweden pharma HUB and patient access support service market, by service type, 2021 - 2033 (USD Million)
  • Table 28 Sweden pharma HUB and patient access support service market, by service delivery type, 2021 - 2033 (USD Million)
  • Table 29 Norway pharma HUB and patient access support service market, by service type, 2021 - 2033 (USD Million)
  • Table 30 Norway pharma HUB and patient access support service market, by service delivery type, 2021 - 2033 (USD Million)
  • Table 31 Asia Pacific pharma HUB and patient access support service market, by region, 2021 - 2033 (USD Million)
  • Table 32 Asia Pacific pharma HUB and patient access support service market, by service type, 2021 - 2033 (USD Million)
  • Table 33 Asia Pacific pharma HUB and patient access support service market, by service delivery type, 2021 - 2033 (USD Million)
  • Table 34 China pharma HUB and patient access support service market, by service type, 2021 - 2033 (USD Million)
  • Table 35 China pharma HUB and patient access support service market, by service delivery type, 2021 - 2033 (USD Million)
  • Table 36 Japan pharma HUB and patient access support service market, by service type, 2021 - 2033 (USD Million)
  • Table 37 Japan pharma HUB and patient access support service market, by service delivery type, 2021 - 2033 (USD Million)
  • Table 38 India pharma HUB and patient access support service market, by service type, 2021 - 2033 (USD Million)
  • Table 39 South Korea pharma HUB and patient access support service market, by service type, 2021 - 2033 (USD Million)
  • Table 40 South Korea pharma HUB and patient access support service market, by service delivery type, 2021 - 2033 (USD Million)
  • Table 41 Australia pharma HUB and patient access support service market, by service type, 2021 - 2033 (USD Million)
  • Table 42 Australia pharma HUB and patient access support service market, by service delivery type, 2021 - 2033 (USD Million)
  • Table 43 Thailand pharma HUB and patient access support service market, by service type, 2021 - 2033 (USD Million)
  • Table 44 Thailand pharma HUB and patient access support service market, by service delivery type, 2021 - 2033 (USD Million)
  • Table 45 Latin America pharma HUB and patient access support service market, by region, 2021 - 2033 (USD Million)
  • Table 46 Latin America pharma HUB and patient access support service market, by service type, 2021 - 2033 (USD Million)
  • Table 47 Latin America pharma HUB and patient access support service market, by service delivery type, 2021 - 2033 (USD Million)
  • Table 48 Brazil pharma HUB and patient access support service market, by service type, 2021 - 2033 (USD Million)
  • Table 49 Brazil pharma HUB and patient access support service market, by service delivery type, 2021 - 2033 (USD Million)
  • Table 50 Argentina pharma HUB and patient access support service market, by service type, 2021 - 2033 (USD Million)
  • Table 51 Argentina pharma HUB and patient access support service market, by service delivery type, 2021 - 2033 (USD Million)
  • Table 52 MEA pharma HUB and patient access support service market, by region, 2021 - 2033 (USD Million)
  • Table 53 MEA pharma HUB and patient access support service market, by service type, 2021 - 2033 (USD Million)
  • Table 54 MEA pharma HUB and patient access support service market, by service delivery type, 2021 - 2033 (USD Million)
  • Table 55 South Africa pharma HUB and patient access support service market, by service type, 2021 - 2033 (USD Million)
  • Table 56 South Africa pharma HUB and patient access support service market, by service delivery type, 2021 - 2033 (USD Million)
  • Table 57 Saudi Arabia pharma HUB and patient access support service market, by service type, 2021 - 2033 (USD Million)
  • Table 58 Saudi Arabia pharma HUB and patient access support service market, by service delivery type, 2021 - 2033 (USD Million)
  • Table 59 UAE pharma HUB and patient access support service market, by service type, 2021 - 2033 (USD Million)
  • Table 60 UAE pharma HUB and patient access support service market, by service delivery type, 2021 - 2033 (USD Million)
  • Table 61 Kuwait pharma HUB and patient access support service market, by service type, 2021 - 2033 (USD Million)
  • Table 62 Kuwait pharma HUB and patient access support service market, by service delivery type, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Pharma HUB and patient access support service market: market outlook
  • Fig. 9 Credentialing software and services competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Pharma HUB and patient access support service market driver impact
  • Fig. 15 Pharma HUB and patient access support service market restraint impact
  • Fig. 16 Pharma HUB and patient access support service market strategic initiatives analysis
  • Fig. 17 Pharma HUB and patient access support service market: Service type movement analysis
  • Fig. 18 Pharma HUB and patient access support service market: Service type outlook and key takeaways
  • Fig. 19 Program enrollment market estimates and forecast, 2021 - 2033
  • Fig. 20 Order processing market estimates and forecast, 2021 - 2033
  • Fig. 21 Application processing market estimates and forecast, 2021 - 2033
  • Fig. 22 Ease of enrollment (through phone, face, portal, or app) market estimates and forecast, 2021 - 2033
  • Fig. 23 Program data market estimates and forecast, 2021 - 2033
  • Fig. 24 Treatment navigators market estimates and forecast, 2021 - 2033
  • Fig. 25 Process flows and standard operating procedures market estimates and forecast, 2021 - 2033
  • Fig. 26 Program literature and scripts market estimates and forecast, 2021 - 2033
  • Fig. 27 Care team training market estimates and forecast, 2021 - 2033
  • Fig. 28 Systems testing and optimization market estimates and forecast, 2021 - 2033
  • Fig. 29 Reimbursement services/affordability services market estimates and forecast, 2021 - 2033
  • Fig. 30 Clinical educator market estimates and forecast, 2021 - 2033
  • Fig. 31 Coordination of specialty pharmacy/dispensing market estimates and forecast, 2021 - 2033
  • Fig. 32 Others market estimates and forecast, 2021 - 2033
  • Fig. 33 Pharma HUB and patient access support service market: Service delivery type movement analysis
  • Fig. 34 Pharma HUB and patient access support service market: Service delivery type outlook and key takeaways
  • Fig. 35 Integrated services market estimates and forecast, 2021 - 2033
  • Fig. 36 Standalone services market estimates and forecast, 2021 - 2033
  • Fig. 37 Pharma HUB and patient access support service market: Regional movement analysis
  • Fig. 38 Pharma HUB and patient access support service market: Regional outlook and key takeaways
  • Fig. 39 Pharma HUB and patient access support service market share and leading players
  • Fig. 40 North America market share and leading players
  • Fig. 41 Europe market share and leading players
  • Fig. 42 Asia Pacific market share and leading players
  • Fig. 43 Latin America market share and leading players
  • Fig. 44 Middle East & Africa market share and leading players
  • Fig. 45 North America: SWOT
  • Fig. 46 Europe SWOT
  • Fig. 47 Asia Pacific SWOT
  • Fig. 48 Latin America SWOT
  • Fig. 49 MEA SWOT
  • Fig. 50 North America, by country
  • Fig. 51 North America
  • Fig. 52 North America market estimates and forecasts, 2021 - 2033
  • Fig. 53 U.S.
  • Fig. 54 U.S market estimates and forecasts, 2021 - 2033
  • Fig. 55 Canada
  • Fig. 56 Canada market estimates and forecasts, 2021 - 2033
  • Fig. 57 Mexico
  • Fig. 58 Mexico market estimates and forecasts, 2021 - 2033
  • Fig. 59 Europe
  • Fig. 60 Europe market estimates and forecasts, 2021 - 2033
  • Fig. 61 UK
  • Fig. 62 UK market estimates and forecasts, 2021 - 2033
  • Fig. 63 Germany
  • Fig. 64 Germany market estimates and forecasts, 2021 - 2033
  • Fig. 65 France
  • Fig. 66 France market estimates and forecasts, 2021 - 2033
  • Fig. 67 Italy
  • Fig. 68 Italy market estimates and forecasts, 2021 - 2033
  • Fig. 69 Spain
  • Fig. 70 Spain market estimates and forecasts, 2021 - 2033
  • Fig. 71 Denmark
  • Fig. 72 Denmark market estimates and forecasts, 2021 - 2033
  • Fig. 73 Sweden
  • Fig. 74 Sweden market estimates and forecasts, 2021 - 2033
  • Fig. 75 Norway
  • Fig. 76 Norway market estimates and forecasts, 2021 - 2033
  • Fig. 77 Asia Pacific
  • Fig. 78 Asia Pacific market estimates and forecasts, 2021 - 2033
  • Fig. 79 China
  • Fig. 80 China market estimates and forecasts, 2021 - 2033
  • Fig. 81 Japan
  • Fig. 82 Japan market estimates and forecasts, 2021 - 2033
  • Fig. 83 India
  • Fig. 84 India market estimates and forecasts, 2021 - 2033
  • Fig. 85 Thailand
  • Fig. 86 Thailand market estimates and forecasts, 2021 - 2033
  • Fig. 87 South Korea
  • Fig. 88 South Korea market estimates and forecasts, 2021 - 2033
  • Fig. 89 Australia
  • Fig. 90 Australia market estimates and forecasts, 2021 - 2033
  • Fig. 91 Latin America
  • Fig. 92 Latin America market estimates and forecasts, 2021 - 2033
  • Fig. 93 Brazil
  • Fig. 94 Brazil market estimates and forecasts, 2021 - 2033
  • Fig. 95 Argentina
  • Fig. 96 Argentina market estimates and forecasts, 2021 - 2033
  • Fig. 97 Middle East and Africa
  • Fig. 98 Middle East and Africa market estimates and forecasts, 2021 - 2033
  • Fig. 99 South Africa
  • Fig. 100 South Africa market estimates and forecasts, 2021 - 2033
  • Fig. 101 Saudi Arabia
  • Fig. 102 Saudi Arabia market estimates and forecasts, 2021 - 2033
  • Fig. 103 UAE
  • Fig. 104 UAE market estimates and forecasts, 2021 - 2033
  • Fig. 105 Kuwait
  • Fig. 106 Kuwait market estimates and forecasts, 2021 - 2033
  • Fig. 107 Market share of key market players- Pharma HUB and patient access support service market